Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib

MLA

Waleed Kian, et al. “Overcoming CEP85L-ROS1, MKRN1-BRAF and MET Amplification as Rare, Acquired Resistance Mutations to Osimertinib.” Frontiers in Oncology, vol. 13, Feb. 2023. EBSCOhost, https://doi.org/10.3389/fonc.2023.1124949.

APA

Waleed Kian, Bilal Krayim, Hadel Alsana, Betsy Giles, Ofer Purim, Wafeek Alguayn, Farouq Alguayn, Nir Peled, & Laila C. Roisman. (2023). Overcoming CEP85L-ROS1, MKRN1-BRAF and MET amplification as rare, acquired resistance mutations to Osimertinib. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1124949

Chicago

Waleed Kian, Bilal Krayim, Hadel Alsana, Betsy Giles, Ofer Purim, Wafeek Alguayn, Farouq Alguayn, Nir Peled, and Laila C. Roisman. 2023. “Overcoming CEP85L-ROS1, MKRN1-BRAF and MET Amplification as Rare, Acquired Resistance Mutations to Osimertinib.” Frontiers in Oncology 13 (February). doi:10.3389/fonc.2023.1124949.